Developmental effects of 3,4-methylenedioxymethamphetamine: A review

Behavioural Pharmacology

Volumn 19, Issue 2, 2008, Pages 91-111

  Skelton, Matthew R ^a   Williams, Michael T ^a,b   Vorhees, Charles V ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Anxiety; Developmental effects; Memory; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; PAROXETINE; SEROTONIN; SEROTONIN 1A RECEPTOR;

ANXIETY; BEHAVIOR; BRAIN DEVELOPMENT; CHEMICAL STRUCTURE; COGNITION; EXPOSURE VARIABLE; HIPPOCAMPUS; HUMAN; LEARNING TEST; MAZE TEST; MEMORY CONSOLIDATION; NEUROENDOCRINE SYSTEM; NONHUMAN; PERINATAL DEVELOPMENT; REVIEW; SUBSTANCE ABUSE;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; FEMALE; HALLUCINOGENS; LEARNING; MEMORY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGENTS;

EID: 40549095358     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3282f62c76     Document Type: Review

References (149)

1. Able JA, Gudelsky GA, Vorhees CV, Williams MT (2006). 3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol Psychiatry 59:1219-1226.
2. Acquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A, Di CG (2001). Intravenous administration of ecstasy (3,4-methylendioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418:207-211.
3. Aguirre N, Barrionuevo M, Lasheras B, Del Rio J (1998). The role of dopaminergic systems in the perinatal sensitivity to 3,4- methylenedioxymethamphetamine-induced neurotoxicity in rats. J Pharmacol Exp Ther 286:1159-1165.
4. Aguirre N, Barrionuevo M, Ramirez MJ, Del RJ, Lasheras B (1999). Alpha-lipoic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity. NeuroReport 10:3675-3680.
5. Azmitia EC (1999). Serotonin neurons, neuroplasticity, and homeostasis of neural tissue. Neuropsychopharmacology 21:33S-45S.
6. Barnes CA (1979). Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol 93:74-104.
7. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987). 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242:911-916.
8. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159-163.
9. Baumann MH, Wang X, Rothman RB (2007). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189:407-424.
10. Bayer SA, Altman J, Russo RJ, Zhang X (1993). Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83-144.
11. Bernschneider-Reif S, Oxler F, Freudenmann RW (2006). The origin of MDMA ('ecstasy') - separating the facts from the myth. Pharmazie 61:966-972.
12. Bhattacharya SK, Bhattacharya A, Ghosul S (1998). Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): an experimental study. Biogenic Amines 14:217-237.
13. Bogen IL, Haug KH, Myhre O, Fonnum F (2003). Short- and long-term effects of MDMA ('ecstasy') on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43:393-400.
14. Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('Ecstasy') users. Neurology 51:1532-1537.
15. Broening HW, Bacon L, Slikker W Jr (1994). Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3,4- methylenedioxymethamphetamine. J Pharmacol Exp Ther 271:285-293.
16. Broening HW, Bowyer JF, Slikker WJr (1995). Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 275:325-333.
17. Broening HW, Morford LL, Inman-Wood SL, Fukumura M, Vorhees CV (2001). 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J Neurosci 21:3228-3235.
18. Bronson ME, Barrios-Zambrano L, Jiang W, Clark CR, DeRuiter J, Newland MC (1994a). Behavioral and developmental effects of two 3,4- methylenedioxymethamphetamine (MDMA) derivatives. Drug Alcohol Depend 36:161-166.
19. Bronson ME, Jiang W, Clark CR, DeRuiter J (1994b). Effects of designer drugs on the chicken embryo and 1-day-old chicken. Brain Res Bull 34:143-150.
20. Brosnan PG (2001). The hypothalamic pituitary axis in the fetus and newborn. Semin Perinatol 25:371-384.
21. Burchfield DJ, Lucas VW, Abrams RM, Miller RL, DeVane CL (1991). Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA 265:1968-1973.
22. Burns N, Olverman HJ, Kelly PA, Williams BC (1996). Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. Endocr Res 22:601-606.
23. Campbell NG, Koprich JB, Kanaan NM, Lipton JW (2006). MDMA administration to pregnant Sprague-Dawley rats results in its passage to the fetal compartment. Neurotoxicol Teratol 28:459-465.
24. Cernerud L, Eriksson M, Jonsson B, Steneroth G, Zetterstrom R (1996). Amphetamine addiction during pregnancy: 14-year follow-up of growth and school performance. Acta Paediatr 85:204-208.
25. Cho AK, Hiramatsu M, Distefano EW, Chang AS, Jenden DJ (1990). Stereochemical differences in the metabolism of 3,4- methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Dispos 18:686-691.
26. Clancy B, Darlington RB, Finlay BL (2001). Translating developmental time across mammalian species. Neuroscience 105:7-17.
27. Clancy B, Finlay BL, Darlington RB, Anand KJ (2007a). Extrapolating brain development from experimental species to humans. Neurotoxicology 28:931-937.
28. Clancy B, Kersh B, Hyde J, Darlington RB, Anand KJS, Finlay BL (2007b). Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics 5:79-94.
29. Clark RE, Zola SM, Squire LR (2000). Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853-8860.
30. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS (2004). MDMA ('ecstasy'), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 173:318-325.
31. Cohen MA, Skelton MR, Schaefer TL, Gudelsky GA, Vorhees CV, Williams MT (2005). Learning and memory after neonatal exposure to 3,4- methylenedioxymethamphetamine (ecstasy) in rats: Interaction with exposure in adulthood. Synapse 57:148-159.
32. Cohen RS (1998). The love drug. Marching to the beat of ecstasy. Binghamton, NY: Haworth Medical Press.
33. Colado MI, Green AR (1995). The spin trap reagent alpha-phenyl-N-tert- butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol 280:343-346.
34. Colado MI, O'Shea E, Granados R, Misra A, Murray TK, Green AR (1997a). A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol 121:827-833.
35. Colado MI, O'Shea E, Granados R, Murray TK, Green AR (1997b). In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 121:889-900.
36. Cole JC, Sumnall HR, O'Shea E, Marsden CA (2003). Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse. Psychopharmacology (Berl) 166:383-390.
37. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987). Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241:338-345.
38. Crawford CA, Williams MT, Kohutek JL, Choi FY, Yoshida ST, McDougall SA, Vorhees CV (2006). Neonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [(35)S]GTPgammaS binding in adult rats. Brain Res 1077:178-186.
39. Cunningham CL, Fidler TL, Hill KG (2000). Animal models of alcohol's motivational effects. Alcohol Res Health 24:85-92.
40. Dai S, Corrigall WA, Coen KM, Kalant H (1989). Heroin self-administration by rats: influence of dose and physical dependence. Pharmacol Biochem Behav 32:1009-1015.
41. Dasari S, Viele K, Turner AC, Cooper RL (2007). Influence of PCPA and MDMA (ecstasy) on physiology, development and behavior in Drosophila melanogaster. Eur J Neurosci 26:424-438.
42. Davison D, Parrott AC (1997). Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Human Psychopharmacol 12:221-226.
43. De la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26:137-144.
44. EMCDDA. Annual Report 2004. The state of the drugs problem in the European Union and Norway. 2004. Luxemborg, European Monitoring Centre for Drugs and Drug Addiction. Ref Type: Report.
45. Etienne AS, Jeffery KJ (2004). Path integration in mammals. Hippocampus 14:180-192.
46. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G (1995). Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). J Neurosci 15:5476-5485.
47. Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A (2000). MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385-1390.
48. Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001). Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ('ecstasy'): is metabolism a contributory factor? J Pharm Pharmacol 53:1357-1363.
49. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002). The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135:649-656.
50. Galineau L, Belzung C, Ercem K, Bodard S, Guilloteau D, Chalon S (2005). Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat. Dev Brain Res 154:165-176.
51. Giannaccini G, Betti L, Pirone A, Palego L, Fabiani O, Fabbrini L, et al. (2007). Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus. Neurochem Int 51:496-506.
52. Gough B, Ali SF, Slikker W Jr, Holson RR (1991). Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol Biochem Behav 39:619-623.
53. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55:463-508.
54. Grinspoon L, Bakalar JB (1986). Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40:393-404.
55. Gudelsky GA (1996). Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J Neural Transm 103:1397-1404.
56. Gudelsky GA, Nash JF (1996). Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J Neurochem 66:243-249.
57. Gudelsky GA, Yamamoto BK, Nash JF (1994). Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists. Eur J Pharmacol 264:325-330.
58. Hardman HF, Haavik CO, Seevers MH (1973). Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 25:299-309.
59. Herlenius E, Lagercrantz H (2004). Development of neurotransmitter systems during critical periods. Exp Neurol 190 (Suppl 1):S8-S21.
60. Ho E, Karimi-Tabesh L, Koren G (2001). Characteristics of pregnant women who use ecstasy (3,4-methylenedioxymethamphetamine). Neurotoxicol Teratol 23:561-567.
61. Ho YJ, Pawlak CR, Guo L, Schwarting RK (2004). Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res 149:135-144.
62. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31:424-430.
63. Johnson MP, Hoffman AJ, Nichols DE (1986). Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276.
64. Johnston LD, O'Malley PM, Bahman JG, Schulenberg JE (2005a). Monitoring the Future national survey results on drug use, 1975-2004. Vol. I: secondary school students. (NIH Publication No. 05-5727). Bethesda, MD, National Institue on Drug Abuse. Ref Type: Report.
65. Johnston LD, O'Malley PM, Bahman JG, Schulenberg JE (2005b). Monitoring the future national survey results on drug use, 1975-2004. Vol. II: college students and adults ages 19-45. Bethesda, MD: National Institute on Drug Abuse.
66. Kalechstein AD, De La GR, Mahoney JJ III, Fantegrossi WE, Newton TF (2007). MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189:531-537.
67. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ (2002). Functional consequences of perinatal exposure to 3,4- methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137:963-970.
68. Klugman A, Gruzelier J (2003). Chronic cognitive impairment in users of 'ecstasy' and cannabis. World Psychiatry 2:184-190.
69. Koch S, Galloway MP (1997). MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146.
70. Koprich JB, Campbell NG, Lipton JW (2003a). Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain derived neurotrophic factor in the forebrain and brainstem of the rat. Dev Brain Res 147:177-182.
71. Koprich JB, Chen EY, Kanaan NM, Campbell NG, Kordower JH, Lipton JW (2003b). Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol 25:509-517.
72. Kramer K, Azmitia EC, Whitaker-Azmitia PM (1994). In vitro release of [3H]5-hydroxytryptamine from fetal and maternal brain by drugs of abuse. Brain Res Dev Brain Res 78:142-146.
73. Lawn JC (1986). Schedules of controlled substances; scheduling of 3,4-methlenedioxymethamphetamine (MDMA) into schedule I of the controlled substances act. Federal Register 51:36552-36560.
74. Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, et al. (1989). Molecular cloning and expression of brain-derived neurotrophic factor. Nature 341:149-152.
75. Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999). Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-378.
76. Lindsay RM, Wiegand SJ, Altar CA, DiStefano PS (1994). Neurotrophic factors: from molecule to man. Trends Neurosci 17:182-190.
77. Linnarsson S, Bjorklund A, Ernfors P (1997). Learning deficit in BDNF mutant mice. Eur J Neurosci 9:2581-2587.
78. Lupien SJ, McEwen BS (1997). The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev 24:1-27.
79. Mahmood I (1999). Allometric issues in drug development. J Pharm Sci 88:1101-1106.
80. McCreary AC, Bankson MG, Cunningham KA (1999). Pharmacological studies of the acute and chronic effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/ 1D) receptors. J Pharmacol Exp Ther 290:965-973.
81. McElhatton PR, Bateman DN, Evans C, Pughe KR, Worsley AJ (1997). Does prenatal exposure to ecstasy cause congenital malformations? A prospective follow-up of 92 pregnancies. Br J Clin Pharmacol 45:184.
82. McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH (1999). Congenital anomalies after prenatal ecstasy exposure. Lancet 354:1441-1442.
83. McGregor IS, Clemens KJ, Van der PG, Li KM, Hunt GE, Chen F, Lawrence AJ (2003a). Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28:1472-1484.
84. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blokland A, Li KM, et al. (2003b). Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 168:465-474.
85. Mechan AO, Esteban B, O'Shea E, Elliott JM, Colado MI, Green AR (2002). The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol 135:170-180.
86. Meneses A, Perez-Garcia G (2007). 5-HT(1A) receptors and memory. Neurosci Biobehav Rev 31:705-727.
87. Meyer JS, Ali SF (2002). Serotonergic neurotoxicity of MDMA (ecstasy) in the developing rat brain. Ann N Y Acad Sci 965:373-380.
88. Meyer JS, Grande M, Johnson K, Ali SF (2004). Neurotoxic effects of MDMA ('ecstasy') administration to neonatal rats. Int J Dev Neurosci 22:261-271.
89. Mordenti J, Chappell W (1989). The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V, editors. Toxicokinetics in new drug development. New York: Pergamon Press. pp. 42-96.
90. Morley KC, Gallate JE, Hunt GE, Mallet PE, McGregor IS (2001). Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ('ecstasy'). Eur J Pharmacol 433:91-99.
91. Morley KC, Arnold JC, McGregor IS (2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29:648-657.
92. Morris RGM (1981). Spatial localization does not require the presence of local cues. Learn Motiv 12:239-260.
93. Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683.
94. Muller CP, Carey RJ, Huston JP, De Souza Silva MA (2007). Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog Neurobiol 81:133-178.
95. Nair SG, Gudelsky GA (2006). 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat. Psychopharmacology (Berl) 184:182-189.
96. Nash JF, Brodkin J (1991). Microdialysis studies on 3,4- methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors. J Pharmacol Exp Ther 259:820-825.
97. Nash JF, Yamamoto BK (1992). Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 581:237-243.
98. Nash JF Jr, Meltzer HY, Gudelsky GA (1988). Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 245:873-879.
99. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K (1998). Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J Psychopharmacol 12:79-83.
100. Patel TD, Zhou FC (2005). Ontogeny of 5-HT1A receptor expression in the developing hippocampus. Brain Res Dev Brain Res 157:42-57.
101. Piper BJ (2007). A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 29:288-300.
102. Piper BJ, Meyer JS (2006). Increased responsiveness to MDMA in adult rats treated neonatally with MDMA. Neurotoxicol Teratol 28:95-102.
103. Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS (2006). Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 317:838-849.
104. Rice D, Barone S Jr (2000). Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108 (Suppl 3):511-533.
105. Richardson KK (1999). Adolescent pregnancy and substance use. J Obstet Gynecol Neonatal Nurs 28:623-627.
106. Roskoden T, Otten U, Schwegler H (2004). Early postnatal corticosterone administration regulates neurotrophins and their receptors in septum and hippocampus of the rat. Exp Brain Res 154:183-191.
107. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carrol FI, Partilla JS (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
108. Rothman RB, Jayanthi S, Wang X, Dersch CM, Cadet JL, Prisinzano T, et al. (2003). High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50:233-239.
109. Sabol KE, Seiden LS (1998). Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis. Brain Res 806:69-78.
110. Sapolsky RM, Meaney MJ (1986). Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res 396:64-76.
111. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993). Serotonergic recovery after (±) 3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264:1484-1491.
112. Schaefer TL, Ehrman LA, Gudelsky GA, Vorhees CV, Williams MT (2006). A comparison of monoamine and corticosterone levels 24 h following (+) methamphetamine, (±) 3,4-methelynedioxymethamphetamine, cocaine, (+) fenfluramine, or (±) methylphenidate administration in the neonatal rat. J Neurochem 98:1369-1378.
113. Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH (2006). Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J Psychopharmacol 20:456-463.
114. Schmidt CJ, Taylor VL (1987). Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36:4095-4102.
115. Schmidt CJ, Taylor VL (1988). Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol 156:121-131.
116. Shankaran M, Gudelsky GA (1999). A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147:66-72.
117. Shankaran M, Yamamoto BK, Gudelsky GA (1999). Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J Neurochem 72:2516-2522.
118. Shankaran M, Yamamoto BK, Gudelsky GA (2001). Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse 40:55-64.
119. Shulgin AT, Nichols DE (1978). Characterization of three new psychomimetics. In: Stillman RC, Willette RE, editors. The psychopharmacology of hallucinogens. Oxford: Pergamon Press.
120. Skelton MR, Williams MT, Vorhees CV (2006). Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats. Psychopharmacology (Berl) 189:307-318.
121. Skelton MR, Williams MT, Schaefer TL, Vorhees CV (2007). Neonatal (+) methamphetamine increases brain derived neurotrophic factor, but not nerve growth factor, during treatment and results in long-term spatial learning deficits. Psychoneuroendocrinology 32:734-745.
122. Sprague JE, Nichols DE (1995). The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-673.
123. Sprague JE, Preston AS, Leifheit M, Woodside B (2003). Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiol Behav 79:281-287.
124. St Omer VE, Ali SF, Holson RR, Duhart HM, Scalzo FM, Slikker W Jr (1991). Behavioral and neurochemical effects of prenatal methylenedioxymethamphetamine (MDMA) exposure in rats. Neurotoxicol Teratol 13:13-20.
125. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987). Immediate and longterm effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683.
126. Timar J, Gyarmati S, Szabo A, Furst S (2003). Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav Pharmacol 14:199-206.
127. Topic B, Willuhn I, Palomero-Gallagher N, Zilles K, Huston JP, Hasenohrl RU (2007). Impaired maze performance in aged rats is accompanied by increased density of NMDA, 5-HT1A, and alpha-adrenoceptor binding in hippocampus. Hippocampus 17:68-77.
128. Uchtenhagen A, Dobler-Mikola A, Steffen T, Gutzwiller F, Blatter R, Pfeifer S (1999). Prescription of narcotics for heroin addicts. Main results of the Swiss National Cohort Study. Med Prescr of Narcotics. Basel: Karger.
129. Van Tonningen-van Driel M, Garbis-Berkvens JM, Reuvers-Lodewijks WE (1999). Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM). Ned Tijdschr Geneeskd 143:27-31.
130. Vorhees CV (1987). Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of phenytoin. Neurotoxicol Teratol 9:235-241.
131. Vorhees CV, Williams MT (2006). Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 1:848-858.
132. Vorhees CV, Inman-Wood SL, Morford LL, Broening HW, Fukumura M, Moran MS (2000). Adult learning deficits after neonatal exposure to D- methamphetamine: selective effects on spatial navigation and memory. J Neurosci 20:4732-4739.
133. Vorhees CV, Reed TM, Skelton MR, Williams MT (2004). Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning. Int J Dev Neurosci 22:247-259.
134. Vorhees CV, Schaefer TL, Williams MT (2007). Developmental effects of ± -methylenedioxymethamphetamine on spatial vs. path integration learning: effects of dose distribution. Synapse 61:488-499.
135. Wallace TL, Gudelsky GA, Vorhees CV (2001). Alterations in diurnal and nocturnal locomotor activity in rats treated with a monoamine-depleting regimen of methamphetamine or 3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) 153:321-326.
136. West GB, Woodruff WH, Brown JH (2002). Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. Proc Natl Acad Sci U S A 99 (Suppl 1):2473-2478.
137. White CR, Seymour RS (2005). Allometric scaling of mammalian metabolism. J Exp Biol 208:1611-1619.
138. Whitworth TL, Herndon LC, Quick MW (2001). Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. J Neurosci 21:RC192.
139. Williams MT, Inman-Wood SL, Morford LL, McCrea AE, Ruttle AM, Moran MS, et al. (2000). Preweaning treatment with methamphetamine induces increases in both corticosterone and ACTH in rats. Neurotoxicol Teratol 22:751-759.
140. Williams MT, Morford LL, McCrea AE, Wood SL, Vorhees CV (2002). Administration of D,L-fenfluramine to rats produces learning deficits in the Cincinnati water maze but not the Morris water maze: relationship to adrenal cortical output. Neurotoxicol Teratol 24:783-796.
141. Williams MT, Morford LL, Wood SL, Rock SL, McCrea AE, Fukumura M, et al. (2003). Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res 968:89-101.
142. Williams MT, Brown CA, Skelton MR, Vinks AA, Vorhees CV (2004). Absorption and clearance of ± 3,4-methylenedioxymethamphetamine from the plasma of neonatal rats. Neurotoxicol Teratol 26:849-856.
143. Williams MT, Schaefer TL, Ehrman LA, Able JA, Gudelsky GA, Sah R, Vorhees CV (2005). 3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity. Brain Res 1039:97-107.
144. Winslow JT, Insel TR (1990). Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. J Pharmacol Exp Ther 254:212-220.
145. Won L, Bubula N, Heller A (2002). Fetal exposure to (±)- methylenedioxymethamphetamine in utero enhances the development and metabolism of serotonergic neurons in three-dimensional reaggregate tissue culture. Brain Res Dev Brain Res 137:67-73.
146. Yamamoto BK, Spanos LJ (1988). The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur J Pharmacol 148:195-203.
147. Yamamoto BK, Nash JF, Gudelsky GA (1995). Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273:1063-1070.
148. Yeh SY (1997). Effects of salicylate on 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Pharmacol Biochem Behav 58: 701-708.
149. Zakzanis KK, Campbell Z (2006). Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 66:740-741.